Another loophole exploited by the drug industryBMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f354 (Published 22 January 2013) Cite this as: BMJ 2013;346:f354
- Martin D Brunet, general practitioner1
- 1Binscombe Medical Centre, Godalming GU7 3PR, UK
Hitchings and colleagues’ excellent analysis of the methods used by drug companies to maximise profits omitted a new tactic that has resulted in £46m (€55.5m; $74m) additional annual costs to the NHS.1 It exploits the fact that the price of generic drugs is not negotiated with the Department of Health because market forces are meant to keep prices …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial